Aspirin vs Clopidogrel After TAVR

Launched by YONSEI UNIVERSITY · Aug 8, 2022

Keywords

ClinConnect Summary

This clinical trial is studying the best type of medication to prevent complications after a procedure called transcatheter aortic valve replacement (TAVR), which is done for patients with severe aortic stenosis (a narrowing of the heart valve). The trial will compare two medications: aspirin and clopidogrel. After the TAVR procedure, participants will take both medications for four weeks and then be randomly assigned to continue with either aspirin or clopidogrel alone. The goal is to see which medication is more effective at preventing a condition called leaflet thrombosis, where the heart valve does not function properly due to blood clots.

To be eligible for the trial, participants must be over 19 years old, have undergone TAVR for severe aortic stenosis, and be able to provide consent for the study. However, individuals who need longer dual medication treatment or have certain health conditions may not qualify. Participants can expect to be monitored for six months, with specific tests done three months after the procedure to check for any issues with the heart valve. This study is actively recruiting participants and aims to improve care for patients who undergo TAVR.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients \>19 years old
• • 2. Patients who underwent TAVR symptomatic severe AS
• • 3. Provision of informed consent
• Exclusion Criteria:
• • 1. Patients requiring dual antiplatelet therapy longer than 4 weeks
• • 2. Any conditions requiring specific antiplatelet therapy aspirin or clopidogrel
• • 3. History of stroke or transient ischemic attack (TIA) within 6 months
• • 4. Planned major surgery
• • 5. Cardiogenic shock or hemodynamic instability
• • 6. Chronic kidney disease stage 4 or 5 (eGFR \<30mL/min)
• • 7. Valve-in-valve TAVR procedure
• • 8. Hypersensitivity or contraindication to aspirin or clopidogrel
• • 9. Indication for anticoagulation therapy